Skip to main content

Table 3 Univariate and multivariate logistic regression analyses of the risk factors of grade ≥ 2 radiation pneumonitis

From: Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy

Factor

Univariate analysis

Multivariate analysis

P value

OR (95% CI)

P value

OR (95% CI)

Gender

    

 Male

    

 Female

0.649

0.80 (0.30–2.12)

  

Age (years)

    

 ≤ 65

    

 > 65

0.146

0.42 (0.13–1.36)

  

T stage in naïve

    

 T1–2

    

 T3–4

0.099

2.36 (0.85–6.55)

  

Type of mutation

    

 Exon 19-del

0.080

   

 Exon 21 L858R

0.141

0.45 (0.16–1.3)

  

 Others

0.219

3.00 (0.52–17.32)

  

Type of EGFR-TKI

    

 Gefitinib

0.081

 

0.081

 

 Erlotinib

0.641

0.76 (0.24–2.39)

0.808

1.18 (0.32–4.37)

 Icotinib

0.025

0.09 (0.01–0.74)

0.030

0.08 (0.007–0.78)

The treatment model

    

 Simultaneous EGFR-TKI and TRT for first line

0.448

   

 Simultaneous EGFR-TKI, chemotherapy and TRT for first line

0.384

1.76 (0.49–6.34)

  

 Previous chemotherapy, simultaneous EGFR-TKI and TRT for second line

0.206

2.50 (0.60–10.34)

  

Dose fractionation

    

 CFRT

    

 SBRT

0.558

1.70 (0.29–9.97)

  

GTV (ml)

    

 ≤ 27

    

 > 27

0.045

2.77 (1.02–7.49)

  

PTV (ml)

    

 ≤ 120

    

 > 120

0.009

4.03 (1.42–11.43)

  

Dose per fraction (Gy)

    

 < 3.00

    

 ≥ 3.00

0.039

0.29 (0.09–0.94)

  

Total dose (Gy)

    

 ≤ 50

    

 > 50

0.752

0.85 (0.30–2.38)

  

Total dose EQD2 (α/β = 3) (Gy)

    

 ≤ 55

    

 > 55

0.103

0.42 (0.15–1.19)

  

Overlap time of EGFR-TKI and TRT (days)

    

 ≤ 20

    

 > 20

0.008

8.52 (1.75–41.41)

0.011

9.11 (1.67–49.65)

Duration of TRT (days)

    

 ≤ 33

    

 > 33

0.048

3.05 (1.01–9.21)

  

Ipsilateral lung V30 (%)

    

 ≤ 34

    

 > 34

0.015

7.50 (1.48–38.08)

0.036

7.48 (1.14–49.14)

Timing of TRT was added

    

 TRT was added after the PD in the maintain of TKI

    

 TRT was added without PD in the maintain of TKI

0.631

1.32 (0.43–4.06)

  
  1. The bold text was some risk factor of RP, which were significantly correlated with RP and the p-value < 0.05
  2. EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor, TRT thoracic radiotherapy, CFRT conventional fractional radiotherapy, SBRT stereotactic body radiation therapy, GTV gross tumor volume, PTV plan tumor volume, RP radiation pneumonitis, PD progressive disease